Download PDF
Pharmacopsychiatry 2016; 49(06): 248-253
DOI: 10.1055/s-0042-108202
Original Paper
© Georg Thieme Verlag KG Stuttgart · New York

One-Year Follow-up of Children and Adolescents with Major Depressive Disorder: Relationship between Clinical Variables and Abcb1 Gene Polymorphisms

A. Blázquez
1   Department of Child and Adolescent Psychiatry and Psychology, Institute of Neurosciences, Hospital Clinic de Barcelona, Spain
,
P. Gassó
2   Department of Anatomic Pathology, Pharmacology and Microbiology, University of Barcelona, Spain
3   Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
4   Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain
,
S. Mas
2   Department of Anatomic Pathology, Pharmacology and Microbiology, University of Barcelona, Spain
3   Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
4   Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain
,
M. T. Plana
1   Department of Child and Adolescent Psychiatry and Psychology, Institute of Neurosciences, Hospital Clinic de Barcelona, Spain
,
A. Lafuente
2   Department of Anatomic Pathology, Pharmacology and Microbiology, University of Barcelona, Spain
3   Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
4   Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain
,
L. Lázaro
1   Department of Child and Adolescent Psychiatry and Psychology, Institute of Neurosciences, Hospital Clinic de Barcelona, Spain
3   Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
4   Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain
5   Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Spain
› Author Affiliations
Further Information

Publication History

received 30 November 2015
revised 16 March 2016

accepted 02 May 2016

Publication Date:
16 June 2016 (online)

Also available at
    Permissions and Reprints

Abstract

Introduction: Differences in response to fluoxetine (FLX) may be influenced by certain genes that are involved in FLX transportation (ABCB1). We examined remission and recovery from the index episode in a cohort of patients treated with FLX, and also investigated associations between genetic variants in ABCB1 and remission, recovery, and suicide risk.

Methods: This was a naturalistic 1-year follow-up study of 46 adolescents diagnosed with major depressive disorder (MDD). At 12 months they underwent a diagnostic interview with the K-SADS-PL.

Results: It was found that remission was around 69.5% and recovery 56.5%. Remission and recovery were associated with lower scores on the CDI at baseline, with fewer readmissions and suicide attempts, and with lower scores on the CGI and higher scores on the GAF scale. No relationship was found between ABCB1 and remission or recovery. However, a significant association was observed between the G2677T ABCB1 polymorphism and suicide attempts.

Conclusion: Other factors such as stressful events, family support, and other genetic factors are likely to be involved in MDD outcome.

Key words

fluoxetine - recovery - remission - suicide attempts - ABCB1
 

  • References

  • 1 Birmaher B, Ryan ND, Williamson DE. et al. Childhood and adolescent depression: a review of the past 10 years: part I. J Am Acad Child Adolesc Psychiatry 1996; 35: 1427-1439
    CrossrefPubMedGoogle Scholar
  • 2 Costello E, Pine DS, Hammen C. et al. Development and natural history of mood disorders. Biol Psychiatry 2002; 52: 529-542
    CrossrefPubMedGoogle Scholar
  • 3 Lewinsohn PM, Clarke GN, Seeley JR. et al. Major depression in community adolescents: age at onset, episode duration and time to recurrence. Acad Child Adolesc Psychiatry 1994; 33: 809-818
    PubMedGoogle Scholar
  • 4 Carr A. Depression in young people: description, assessment and evidence-based treatment. Dev Neurorehabil 2008; 11: 3-15
    CrossrefPubMedGoogle Scholar
  • 5 Birmaher B, Arbelaez C, Brent D. Course and outcome of child and adolescent major depressive disorder. Child Adolesc Psychiatr Clin N Am 2002; 11: 619-637
    CrossrefPubMedGoogle Scholar
  • 6 Gould MS, Velting D, Kleinman M. et al. Teenagers’ attitudes about coping strategies and help-seeking behavior for suicidality. J Am Acad Child Adolesc Psychiatry 2004; 43: 1124-1133
    CrossrefPubMedGoogle Scholar
  • 7 Glied S, Pine DS. Consequences and correlates of adolescent depression. Arch Pediatr Adolesc Med 2002; 156: 1009-1114
    CrossrefPubMedGoogle Scholar
  • 8 Dopheide JA. Recognizing and treating depression in children and adolescents. Am J Health Syst Pharm 2002; 63: 233-243
    PubMedGoogle Scholar
  • 9 Lewinsohn PM, Allen NB, Seeley JR. et al. First onset versus recurrence of depression: differential processes of psychosocial risk. J Abnorm Psychol 1999; 108: 483-489
    CrossrefPubMedGoogle Scholar
  • 10 Fombonne E, Wostear G, Cooper V. et al. The Maudsley long-term follow-up of child and adolescent depression. Psychiatric outcomes in adulthood. Br J Psychiatry 2001; 179: 210-217
    CrossrefPubMedGoogle Scholar
  • 11 Emslie GJ. Improving outcome in pediatric depression. Am J Psychiatry 2008; 165: 1-3
    CrossrefPubMedGoogle Scholar
  • 12 Emslie GJ, Heiligenstein JH, Hoog SL. et al. Fluoxetine treatment for prevention of relapse of depression in children and adolescents: a double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry 2004; 43: 1397-1405
    CrossrefPubMedGoogle Scholar
  • 13 Kennard BD, Emslie GJ, Mayes TL. et al. Relapse and recurrence in pediatric depression. Child Adolesc Psychiatr Clin N Am 2006; 15: 1057-1079
    CrossrefPubMedGoogle Scholar
  • 14 Kovacs M, Gatsonis C, Paulauskas SL. et al. Depressive disorders in childhood: IV. A longitudinal study of comorbidity with and risk for anxiety disorders. Arch Gen Psychiatry 1989; 46: 776-782
    CrossrefPubMedGoogle Scholar
  • 15 Essau CA. Course and outcome of major depressive disorder in non-referred adolescents. J Affect Disord 2007; 99: 191-201
    CrossrefPubMedGoogle Scholar
  • 16 Thase ME. Preventing relapse and recurrence of depression: a brief review of therapeutic options. CNS Spectr Suppl 2006; 15: 12-21
    PubMedGoogle Scholar
  • 17 Emslie GJ, Heiligenstein JH, Wagner KD. et al. Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry 22 24: 377-383
    PubMedGoogle Scholar
  • 18 Usala T, Clavenna A, Zuddas A. et al. Randomised controlled trials of selective serotonin reuptake inhibitors in treating depression in children and adolescents: a systematic review and meta-analysis. Eur Neuropsychopharmacol 2008; 18: 62-73
    CrossrefPubMedGoogle Scholar
  • 19 Kronenberg S, Frisch A, Rotberg B. et al. Pharmacogenetics of selective serotonin reuptake inhibitors in paediatric depression and anxiety. Pharmacogenomics 2008; 9: 1725-1736
    CrossrefPubMedGoogle Scholar
  • 20 Treatment for Adolescents with Depression Study Team. The treatment for adolescents with depression study (TADS): outcomes over 1 year of naturalistic follow-up. Am J Psychiatry 2009; 166: 1141-1149
    CrossrefPubMedGoogle Scholar
  • 21 Emslie GJ, Kennard BD, Mayes TL. et al. Fluoxetine versus placebo in preventing relapse of major depression in children and adolescents. Am J Psychiatry 2008; 165: 459-467
    CrossrefPubMedGoogle Scholar
  • 22 Kato M, Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry 2010; 15: 473-500
    CrossrefPubMedGoogle Scholar
  • 23 Gassó P, Rodríguez N, Mas S. et al. Effect of CYP2D6, CYP2C9 and ABCB1 genotypes on fluoxetine plasma concentrations and clinical improvement in children and adolescent patients. Pharmacogenomics J 2014; DOI: 10.1038/tpj.2014.12.
    CrossrefPubMedGoogle Scholar
  • 24 Uhr M, Grauer MT, Yassouridis A. et al. Blood-brain barrier penetration and pharmacokinetics of amitriptyline and its metabolites in p-glycoprotein (abcb1ab) knock-out mice and controls. J Psychiatr Res 2007; 41: 179-188
    CrossrefPubMedGoogle Scholar
  • 25 Dong C, Wong ML, Licinio J. Sequence variations of ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1, CRHR1 and NTRK2: association with major depression and antidepressant response in Mexican-Americans. Mol Psychiatry 2009; 14: 1105-1118
    CrossrefPubMedGoogle Scholar
  • 26 Menu P, Gressier F, Verstuyft C. Antidepressants and ABCB1 gene C3435T functional polymorphism: a naturalistic study. Neuropsychobiology 2010; 62: 193-197
    CrossrefPubMedGoogle Scholar
  • 27 Uhr M, Steckler T, Yassouridis A. et al. Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption. Neuropsychopharmacology 2000; 22: 380-387
    CrossrefPubMedGoogle Scholar
  • 28 Uhr M, Tontsch A, Namendorf C. et al. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron 2008; 57: 203-209
    CrossrefPubMedGoogle Scholar
  • 29 de Klerk OL, Nolte IM, Bet PM. et al. ABCB1 gene variants influence tolerance to selective serotonin reuptake inhibitors in a large sample of Dutch cases with major depressive disorder. Pharmacogenomics J 2013; 13: 349-353 doi:10.1038/tpj.2012.16 Epub 2012 May 29
    CrossrefPubMedGoogle Scholar
  • 30 Breitenstein B, Brückl TM, Ising M. et al. ABCB1 gene variants and antidepressant treatment outcome: A meta-analysis. Am J Med Genet B Neuropsychiatr Genet 2015; 168B: 274-283
    PubMedGoogle Scholar
  • 31 Peñas-Lledó E, Guillaume S, Delgado A. et al. ABCB1 gene polymorphisms and violent suicide attempt among survivors. J Psychiatr Res 2015; 61: 52-56 doi:10.1016/j.jpsychires.2014.12.005
    CrossrefPubMedGoogle Scholar
  • 32 Noordam R, Aarts N, Hofman A. et al. Association between genetic variation in the ABCB1 gene and switching, discontinuation, and dosage of antidepressant therapy: results from the Rotterdam Study. J Clin Psychopharmacol 2013; 33: 546-550
    CrossrefPubMedGoogle Scholar
  • 33 Fabbri C, Serretti A. Pharmacogenetics of major depressive disorder: top genes and pathways toward clinical applications. Curr Psychiatry Rep 2015; 17: 50 doi:10.1007/s11920-015-0594-9
    CrossrefPubMedGoogle Scholar
  • 34 Fujii T, Ota M, Hori H. et al. Association between the functional polymorphism (C3435T) of the gene encoding P-glycoprotein (ABCB1) and major depressive disorder in the Japanese population. J Psychiatr Res 2012; 46: 555-559
    CrossrefPubMedGoogle Scholar
  • 35 Blázquez A, Mas S, Plana MT. et al. Plasma fluoxetine concentrations and clinical improvement in an adolescent sample diagnosed with major depressive disorder, obsessive-compulsive disorder, or generalized anxiety disorder. J Clin Psychopharmacol 2014; 34: 318-326
    CrossrefPubMedGoogle Scholar
  • 36 Ulloa RE, Ortiz S, Higuera F. et al. [Interrater reliability of the Spanish version of Schedule for Affective Disorders and Schizophrenia for School-Age Children – Present and Lifetime version (K-SADS-PL)]. Actas Esp Psiquiatr 2006; 34: 36-40
    PubMedGoogle Scholar
  • 37 Kaufman J, Birmaher B, Brent D. et al. Schedule for Affective Disorders and Schizophrenia for School-Age Children – Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 1997; 36: 980-998
    PubMedGoogle Scholar
  • 38 Frank E, Prien RF, Jarrett RB. et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 1991; 48: 851-855
    CrossrefPubMedGoogle Scholar
  • 39 Kovacs M. The Children’s Depression Inventory Manual. New York: Multi-Health Systems; 1992
    Google Scholar
  • 40 Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised. Bethesda MD: United States Department of Health, Education, and Welfare; 1976
    Google Scholar
  • 41 Luborsky L. Clinician’s judgments of mental health: A proposed scale. Arch Gen Psychiatry 1962; 7: 407-417
    CrossrefPubMedGoogle Scholar
  • 42 Shaffer D, Gould MS, Brasic J. et al. A children’s global assessment scale (CGAS). Arch Gen Psychiatry 1983; 40: 1228-1231
    CrossrefPubMedGoogle Scholar
  • 43 Dunn V, Goodyer IM. Longitudinal investigation into childhood and adolescence-onset depression: psychiatric outcome in early adulthood. Br J Psychiatry 2006; 188: 216-222
    CrossrefPubMedGoogle Scholar
  • 44 March J, Silva S, Vitiello B. The Treatment for Adolescents with Depression Study (TADS): methods and message at 12 weeks. J Am Acad Child Adolesc Psychiatry 2006; 45: 1393-1403
    CrossrefPubMedGoogle Scholar
  • 45 Kennard BD, Silva SG, Tonev S. et al. Remission and recovery in the Treatment for Adolescents with Depression Study (TADS): acute and long-term outcomes. J Am Acad Child Adolesc Psychiatry 2009; 48: 186-195
    CrossrefPubMedGoogle Scholar
  • 46 Gledhill J, Garralda ME. The short-term outcome of depressive disorder in adolescents attending primary care: a cohort study. Soc Psychiatry Psychiatr Epidemiol 2011; 46: 993-1002
    CrossrefPubMedGoogle Scholar
  • 47 Tsapakis EM, Soldani F, Tondo L. et al. Efficacy of antidepressants in juvenile depression: meta-analysis. Br J Psychiatry 2008; 193: 10-17
    CrossrefPubMedGoogle Scholar
  • 48 Emslie GJ, Rush AJ, Weinberg WA. et al. Fluoxetine in child and adolescent depression: acute and maintenance treatment. Depress Anxiety 1998; 7: 32-39
    CrossrefPubMedGoogle Scholar
  • 49 Melvin GA, Dudley AL, Gordon MS. What happens to depressed adolescents? A follow-up study into early adulthood. J Affect Disord 2013; 151: 298-305
    CrossrefPubMedGoogle Scholar
  • 50 Lewinsohn PM, Clarke GN, Seeley JR. Major depression in community adolescents: age at onset, episode duration, and time to recurrence. J Am Acad Child Adolesc Psychiatry 1994; 33: 809-818
    CrossrefPubMedGoogle Scholar
  • 51 Harrington R, Fudge H, Rutter M. et al. Adult outcomes of childhood and adolescent depression: I. Psychiatric status. Arch Gen Psychiatry 1991; 47: 465-473
    PubMedGoogle Scholar
  • 52 Geller B, Zimmerman B, Williams M. Adult psychosocial outcome of prepubertal major depressive disorder. J Am Acad Child Adolesc Psychiatry 2001; 40: 673-677
    CrossrefPubMedGoogle Scholar
  • 53 Kovacs M, Goldston D, Gatsonis C. Suicidal behaviors and childhood-onset depressive disorders: a longitudinal investigation. J Am Acad Child Adolesc Psychiatry 1993; 32: 8-20
    CrossrefPubMedGoogle Scholar
  • 54 Williams JMG, Crane C, Barnhofer T. Recurrence of suicidal ideation across depressive episodes. J Affect Disord 2006; 91: 189-194
    CrossrefPubMedGoogle Scholar
  • 55 Eichelbaum M, Fromm MF, Schwab M. Clinical aspects of the MDR1 (ABCB1) gene polymorphism. Ther Drug Monit 2004; 26: 180-185
    CrossrefPubMedGoogle Scholar
  • 56 Nikisch G, Eap CB, Baumann P. Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: a pilot study. Pharmacol Res 2008; 58: 344-347
    CrossrefPubMedGoogle Scholar
  • 57 Singh AB, Bousman CA, Ng CH. ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression. Transl Psychiatry 2012; DOI: 10.1038/tp.2012.115.
    CrossrefPubMedGoogle Scholar
  • 58 Sarginson JE, Lazzeroni LC, Ryan HS. et al. ABCB1 (MDR1) polymorphisms and antidepressant response in geriatric depression. Pharmacogenet Genomics 2010; 20: 467-475 doi:10.1097/FPC.0b013e32833b593a
    CrossrefPubMedGoogle Scholar
  • 59 Niitsu T, Fabbri C, Bentini F. et al. Pharmacogenetics in major depression: a comprehensive meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry 2013; 45: 183-194
    CrossrefPubMedGoogle Scholar
  • 60 Perroud N, Bondolfi G, Uher R. et al. Clinical and genetic correlates of suicidal ideation during antidepressant treatment in a depressed outpatient sample. Pharmacogenomics 2011; 12: 365-377
    CrossrefPubMedGoogle Scholar
  • 61 Boiso Moreno S, Zackrisson AL, Jakobsen Falk I. et al. ABCB1 gene polymorphisms are associated with suicide in forensic autopsies. Pharmacogenetics 2013; 23: 463-469
    PubMedGoogle Scholar
  • 62 Charlier C, Broly F, Lhermitte M. et al. Polymorphisms in the CYP2D6 gene: Association with plasma concentrations of fluoxetine and paroxetine. Ther Drug Monit 2003; 25: 738-742
    CrossrefPubMedGoogle Scholar